Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy
Medical & Biological Engineering & Computing · 2025
DOI: 10.1007/s11517-024-03233-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical & Biological Engineering & Computing, 2025. Verfasst von Rishabh Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Amity Stem Cell Institute, Amity Medical School, Amity University Haryana, Amity Education Valley, Panchgaon, Manesar (Gurugram), Haryana, 122413, In…. Hauptthemen laut MEDLINE: Neoplasms, Tumor Hypoxia, Blood Substitutes. Die Arbeit nennt 152 Literaturangaben. Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board (SERB).
Abstract (Originalsprache)
The blood plays a vital role in the human body and serves as an intermediary between various physiological systems and organs. White blood cells, which are a part of the immune system, defend against infections and regulate the body temperature and pH balance. Blood platelets play a crucial role in clotting, the prevention of excessive bleeding, and the promotion of healing. Blood also serves as a courier system that transports hormones to facilitate communication and synchronization between different organs and systems in the body. The circulatory system, comprised of arteries, veins, and capillaries, plays a crucial role in the efficient transportation and connection of vital nutrients and oxygen. Despite the importance of natural blood, there are often supply shortages, compatibility issues, and medical conditions, which make alternatives such as artificial blood necessary. This is particularly relevant in cancer treatment, which was the focus of our study. In this study, we investigated the potential of artificial blood in cancer therapy, specifically to address tumor hypoxia. We also examined the potential of red blood cell substitutes such as hemoglobin-based oxygen carriers and perfluorocarbons. Additionally, we examined the production of hemoglobin using E. coli and the role of hemoglobin in oncogenesis. Furthermore, we explored the potential use of artificial platelets for cancer treatment. Our study emphasizes the significance of artificial blood in improving cancer treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity Stem Cell Institute, Amity Medical School, Amity University Haryana, Amity Education Valley, Panchgaon, Manesar (Gurugram), Haryana, 122413, India.
- Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
- Amity Institute of Nanotechnology, Amity School of Applied Sciences, Amity University Haryana, Panchgaon, Manesar (Gurugram), Haryana, 122413, India. lkrishnia@ggn.amity.edu.
- Amity Stem Cell Institute, Amity Medical School, Amity University Haryana, Amity Education Valley, Panchgaon, Manesar (Gurugram), Haryana, 122413, India. mkkashyap@ggn.amity.edu.
Förderung
- Indian Council of Medical Research
- Science and Engineering Research Board (SERB)
Zitieren
APA
Sharma, R., Kashyap, M., Zayed, H., Krishnia, L., & Kashyap, M. K. (2025). Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy. Medical & Biological Engineering & Computing. https://doi.org/10.1007/s11517-024-03233-6
Vancouver
Sharma R, Kashyap M, Zayed H, Krishnia L, Kashyap MK. Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy. Medical & Biological Engineering & Computing. 2025. doi:10.1007/s11517-024-03233-6
BibTeX
@article{Sharma2025,
author = {Sharma, Rishabh and Kashyap, Manju and Zayed, Hatem and Krishnia, Lucky and Kashyap, Manoj Kumar},
title = {Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy},
journal = {Medical & Biological Engineering & Computing},
year = {2025},
doi = {10.1007/s11517-024-03233-6}
}
EUVIMED